Plus   Neg

Merck: FDA Grants Priority Review To SBLA For Keytruda Plus Chemotherapy

Merck & Co. Inc. (MRK) said Thursday that the U.S. Food and Drug Administration has granted priority review for a new supplemental Biologics License Application or sBLA for KEYTRUDA in combination with platinum and fluoropyrimidine based chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the esophagus and gastroesophageal junction (GEJ).

This sBLA is based on data from the pivotal Phase 3 KEYNOTE-590 trial. In the trial, KEYTRUDA plus chemotherapy demonstrated significant improvements in the primary endpoints of overall survival (OS) and progression-free survival (PFS), versus chemotherapy in these patients regardless of PD-L1 expression status and tumor histology. KEYTRUDA is Merck's anti-PD-1 therapy.

Merck said it presented the data at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

The FDA has set a Prescription Drug User Fee Act date (PDUFA date) as April 13, 2021.

KEYTRUDA is currently approved in the U.S., China and Japan as monotherapy for the second-line treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus.

Merck is continuing to study KEYTRUDA across multiple settings and stages of gastrointestinal cancer - including gastric, hepatobiliary, esophageal, pancreatic, colorectal and anal cancers - through its clinical program.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Canada's Olymel S.E.C./L.P. has recalled around 6,804 pounds of ready-to-eat or RTE ham products for potential contamination with Salmonella Enteritidis, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS announced. ViacomCBS Inc. announced plans to combine CBS News and the CBS Television Stations. The journalistic and business operations of both will be combined into one divisional and leadership structure. Neeraj Khemlani and Wendy McMahon were appointed as presidents and co-heads of the newly formed division, effective early next month. Retail major Target Corp. is recalling about 44,350 units of Cat & Jack Baby Heart Ears Rompers, citing choking risks to children, the U.S. Consumer Product Safety Commission said in a statement. The recall involves rompers sold in various sizes from newborn to 24 months. The rompers were manufactured in Vietnam, and sold at Target stores across the United States and online.
Follow RTT